CTI BioPharma Competitors

Lexicon Pharmaceuticals (NASDAQ:LXRX) and CTI BioPharma (NASDAQ:CTIC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Institutional & Insider Ownership

84.6% of Lexicon Pharmaceuticals shares are held by institutional investors. Comparatively, 52.5% of CTI BioPharma shares are held by institutional investors. 6.4% of Lexicon Pharmaceuticals shares are held by company insiders. Comparatively, 6.9% of CTI BioPharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Lexicon Pharmaceuticals and CTI BioPharma's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Lexicon Pharmaceuticals and CTI BioPharma's revenue, earnings per share and valuation.

Lexicon Pharmaceuticals has higher revenue and earnings than CTI BioPharma. CTI BioPharma is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Lexicon Pharmaceuticals has a beta of 2.09, suggesting that its share price is 109% more volatile than the S&P 500. Comparatively, CTI BioPharma has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Lexicon Pharmaceuticals and CTI BioPharma, as reported by MarketBeat.com.

Lexicon Pharmaceuticals currently has a consensus target price of $9.40, indicating a potential upside of 85.40%. CTI BioPharma has a consensus target price of $7.25, indicating a potential upside of 198.35%. Given CTI BioPharma's stronger consensus rating and higher possible upside, analysts plainly believe CTI BioPharma is more favorable than Lexicon Pharmaceuticals.

Summary

CTI BioPharma beats Lexicon Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Intercept Pharmaceuticals (NASDAQ:ICPT) and CTI BioPharma (NASDAQ:CTIC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations for Intercept Pharmaceuticals and CTI BioPharma, as reported by MarketBeat.com.

Intercept Pharmaceuticals currently has a consensus target price of $50.6957, indicating a potential upside of 128.98%. CTI BioPharma has a consensus target price of $7.25, indicating a potential upside of 198.35%. Given CTI BioPharma's stronger consensus rating and higher possible upside, analysts plainly believe CTI BioPharma is more favorable than Intercept Pharmaceuticals.

Profitability

This table compares Intercept Pharmaceuticals and CTI BioPharma's net margins, return on equity and return on assets.

Institutional & Insider Ownership

85.8% of Intercept Pharmaceuticals shares are held by institutional investors. Comparatively, 52.5% of CTI BioPharma shares are held by institutional investors. 23.7% of Intercept Pharmaceuticals shares are held by company insiders. Comparatively, 6.9% of CTI BioPharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Intercept Pharmaceuticals and CTI BioPharma's revenue, earnings per share and valuation.

CTI BioPharma has lower revenue, but higher earnings than Intercept Pharmaceuticals. CTI BioPharma is trading at a lower price-to-earnings ratio than Intercept Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Intercept Pharmaceuticals has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500. Comparatively, CTI BioPharma has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.

Esperion Therapeutics (NASDAQ:ESPR) and CTI BioPharma (NASDAQ:CTIC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, profitability and risk.

Risk & Volatility

Esperion Therapeutics has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500. Comparatively, CTI BioPharma has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500.

Valuation & Earnings

This table compares Esperion Therapeutics and CTI BioPharma's revenue, earnings per share (EPS) and valuation.

CTI BioPharma has lower revenue, but higher earnings than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than CTI BioPharma, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

52.5% of CTI BioPharma shares are owned by institutional investors. 7.7% of Esperion Therapeutics shares are owned by insiders. Comparatively, 6.9% of CTI BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Esperion Therapeutics and CTI BioPharma's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings for Esperion Therapeutics and CTI BioPharma, as reported by MarketBeat.com.

Esperion Therapeutics currently has a consensus target price of $50.60, indicating a potential upside of 94.47%. CTI BioPharma has a consensus target price of $7.25, indicating a potential upside of 198.35%. Given CTI BioPharma's stronger consensus rating and higher possible upside, analysts clearly believe CTI BioPharma is more favorable than Esperion Therapeutics.

Summary

CTI BioPharma beats Esperion Therapeutics on 10 of the 15 factors compared between the two stocks.

ORIC Pharmaceuticals (NASDAQ:ORIC) and CTI BioPharma (NASDAQ:CTIC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk.

Earnings and Valuation

This table compares ORIC Pharmaceuticals and CTI BioPharma's gross revenue, earnings per share and valuation.

ORIC Pharmaceuticals has higher earnings, but lower revenue than CTI BioPharma.

Profitability

This table compares ORIC Pharmaceuticals and CTI BioPharma's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for ORIC Pharmaceuticals and CTI BioPharma, as provided by MarketBeat.com.

ORIC Pharmaceuticals currently has a consensus price target of $43.7143, indicating a potential upside of 122.01%. CTI BioPharma has a consensus price target of $7.25, indicating a potential upside of 198.35%. Given CTI BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe CTI BioPharma is more favorable than ORIC Pharmaceuticals.

Institutional and Insider Ownership

73.4% of ORIC Pharmaceuticals shares are held by institutional investors. Comparatively, 52.5% of CTI BioPharma shares are held by institutional investors. 6.9% of CTI BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

CTI BioPharma (NASDAQ:CTIC) and Veru (NASDAQ:VERU) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Earnings & Valuation

This table compares CTI BioPharma and Veru's top-line revenue, earnings per share and valuation.

Veru has higher revenue and earnings than CTI BioPharma. Veru is trading at a lower price-to-earnings ratio than CTI BioPharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares CTI BioPharma and Veru's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for CTI BioPharma and Veru, as reported by MarketBeat.

CTI BioPharma currently has a consensus target price of $7.25, suggesting a potential upside of 198.35%. Veru has a consensus target price of $19.25, suggesting a potential upside of 97.23%. Given CTI BioPharma's higher probable upside, research analysts plainly believe CTI BioPharma is more favorable than Veru.

Risk & Volatility

CTI BioPharma has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, Veru has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500.

Institutional and Insider Ownership

52.5% of CTI BioPharma shares are owned by institutional investors. Comparatively, 23.3% of Veru shares are owned by institutional investors. 6.9% of CTI BioPharma shares are owned by insiders. Comparatively, 26.1% of Veru shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

CTI BioPharma (NASDAQ:CTIC) and ZIOPHARM Oncology (NASDAQ:ZIOP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Earnings & Valuation

This table compares CTI BioPharma and ZIOPHARM Oncology's top-line revenue, earnings per share and valuation.

CTI BioPharma has higher revenue and earnings than ZIOPHARM Oncology. ZIOPHARM Oncology is trading at a lower price-to-earnings ratio than CTI BioPharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares CTI BioPharma and ZIOPHARM Oncology's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for CTI BioPharma and ZIOPHARM Oncology, as reported by MarketBeat.

CTI BioPharma currently has a consensus target price of $7.25, suggesting a potential upside of 198.35%. ZIOPHARM Oncology has a consensus target price of $5.90, suggesting a potential upside of 80.98%. Given CTI BioPharma's stronger consensus rating and higher probable upside, research analysts plainly believe CTI BioPharma is more favorable than ZIOPHARM Oncology.

Risk & Volatility

CTI BioPharma has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, ZIOPHARM Oncology has a beta of 2.28, suggesting that its share price is 128% more volatile than the S&P 500.

Institutional and Insider Ownership

52.5% of CTI BioPharma shares are owned by institutional investors. Comparatively, 48.0% of ZIOPHARM Oncology shares are owned by institutional investors. 6.9% of CTI BioPharma shares are owned by insiders. Comparatively, 2.3% of ZIOPHARM Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

CTI BioPharma beats ZIOPHARM Oncology on 8 of the 13 factors compared between the two stocks.